e-learning
resources
Munich 2014
Monday, 08.09.2014
Pulmonary hypertension: novel targets and drugs
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Treprostinil pharmacokinetics in rats are extended using inhaled prodrug formulations
V. Malinin, Z. Li, R. Chapman, F. Leifer, D. Omiatek, J. Ong, D. Salvail, C. Laurent, W. Perkins (Monmouth Junction, United States Of America; Sherbrooke, Canada)
Source:
International Congress 2014 – Pulmonary hypertension: novel targets and drugs
Session:
Pulmonary hypertension: novel targets and drugs
Session type:
Thematic Poster Session
Number:
2367
Disease area:
Pulmonary vascular diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
V. Malinin, Z. Li, R. Chapman, F. Leifer, D. Omiatek, J. Ong, D. Salvail, C. Laurent, W. Perkins (Monmouth Junction, United States Of America; Sherbrooke, Canada). Treprostinil pharmacokinetics in rats are extended using inhaled prodrug formulations. Eur Respir J 2014; 44: Suppl. 58, 2367
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
The definition of pulmonary hypertension: history, practical implications and current controversies
Should we screen for hereditary pulmonary hypertension?
Patient with ankylosing spondylitis and pulmonary hypertension
Related content which might interest you:
Prolonged activity of inhaled treprostinil prodrug nanoparticles in a rat model of pulmonary arterial hypertension
Source: International Congress 2014 – Pulmonary hypertension: novel targets and drugs
Year: 2014
Nebivolol and pulmonary hypertension
Source: International Congress 2014 – Pulmonary hypertension: pathobiology
Year: 2014
Epoprostenol dosing by concomitant therapies in the PROSPECT registry
Source: International Congress 2014 – Pulmonary hypertension: clinical management
Year: 2014
The flavonoid quercetin reverses monocrotaline-induced pulmonary hypertension
Source: International Congress 2014 – Pulmonary hypertension: novel targets and drugs
Year: 2014
Incorporation into lipid nanoparticles extends the duration of activity of treprostinil in an acute hypoxia rat model of pulmonary arterial hypertension
Source: International Congress 2014 – Pulmonary hypertension: novel targets and drugs
Year: 2014
Population pharmacokinetics (PK) of riociguat in patients (pts) with renal and hepatic impairment
Source: International Congress 2014 – Pulmonary hypertension: novel targets and drugs
Year: 2014
Immune signatures in pulmonary arterial hypertension
Source: International Congress 2014 – Pulmonary hypertension: novel targets and drugs
Year: 2014
Female pulmonary arterial hypertension is associated with decreased microRNA96 expression
Source: International Congress 2014 – Pulmonary hypertension: novel targets and drugs
Year: 2014
Endothelial-to-mesenchymal transition in pulmonary hypertension
Source: International Congress 2014 – Pulmonary hypertension: novel targets and drugs
Year: 2014
Chronic thromboembolic vasculopathy with exercise induced PH but normal resting haemodynamics
Source: International Congress 2014 – Chronic thromboembolic pulmonary hypertension
Year: 2014
Long-term screening for pulmonary hypertension after pulmonary embolism
Source: International Congress 2014 – Chronic thromboembolic pulmonary hypertension
Year: 2014
Pulmonary arterial hypertension – A single-centre experience
Source: International Congress 2014 – Pulmonary hypertension: clinical management
Year: 2014
Exercise-induced pulmonary hypertension in patients with systemic sclerosis: Pilot-study
Source: International Congress 2014 – Pulmonary hypertension: clinical management
Year: 2014
Treprostinil prodrugs for pulmonary arterial hypertension evaluated in cAMP profiling studies in live CHO-K1 cells
Source: International Congress 2014 – Pulmonary hypertension: novel targets and drugs
Year: 2014
LATE-BREAKING ABSTRACT: Riociguat for the treatment of pulmonary arterial hypertension (PAH): 2-year results from the PATENT-2 long-term extension
Source: International Congress 2014 – New technologies and biomarkers in lung disease
Year: 2014
An overview of thrombolytic treatment for pulmonary embolism: A single center experience
Source: International Congress 2014 – Acute pulmonary embolism
Year: 2014
Prognosis factors of recurrent pulmonary thromboembolism
Source: International Congress 2014 – Acute pulmonary embolism
Year: 2014
Specific pulmonary arterial hypertension therapy in COPD patients with severe pulmonary hypertension
Source: International Congress 2014 – Pulmonary hypertension in lung disease
Year: 2014
Inflammasome ASC-knock out attenuates the development of pulmonary hypertension caused by chronic alveolar hypoxia
Source: International Congress 2014 – Pulmonary hypertension: pathobiology
Year: 2014
Long-term data from the Swiss pulmonary hypertension registry
Source: International Congress 2014 – Pulmonary hypertension: clinical management
Year: 2014
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept